Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.
Israeli medical device developer Magenta Medical recently closed a $55 million financing round. The new funding will be used primarily to help Magenta attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
A Roche drug that failed as a treatment for neurological disorders is now the lead program for Disc Medicine. CEO John Quisel said Roche's clinical data showed the small molecule's promise addressing a rare blood disorder and now the biotech startup has $90 million to advance that drug and another one into Phase 2 testing.
Incubated by OribMed and led by Ariad Pharmaceuticals veterans, Theseus Pharmaceuticals unveiled $100 million in Series B financing to develop the next generation of tyrosine kinase inhibitors, a type of cancer drug. The company expects to enter the clinic by the end of 2021.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
The Suzhou-based firm plans to use the money to advance its therapies, currently in clinical development in China and Australia.
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
How to turn analytics into actual policy outcomes.
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.
So far, investments from OrbiMed Israel Partners II include gene therapy company, logicBio and a digital health company focused on protecting patient data in the context of medical research, called MDClone.
A high profile Super Bowl commercial by pharmaceutical company Valeant and the UK's health system pledged to spend $6.1 billion to go paperless and help shift patients with chronic conditions to remote monitoring.